Review: Pneumococcal conjugate vaccines effective at preventing child deaths

Oct 19, 2009

A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths. The findings were based on a systematic review of the results of 6 randomized and controlled trials conducted in the US, Africa, Philippines, and Finland. Eighty percent of children were less likely to develop vaccine-type IPD, 58% all-serotype IPD, and 27% x-ray defined pneumonia than children who did not receive the vaccine. Eleven percent of child deaths were also prevented. In total, 113,044 children were included in the six trials - 57,015 children in the PCV group and 56,029 in the control group.

"Pneumococcal disease is driving a global health crisis, particularly in the ," said Marilla G. Lucero of the Research Institute for and primary author of the study. "This study underscores the value of vaccines in preventing this deadly disease and saving children's lives."

Pneumococcal disease, or Streptoccoccus pneumoniae, is a leading cause of pneumonia, meningitis, sepsis and other life-threatening ailments. It takes the lives of 1.6 million people each year, including more than 800,000 children despite the existence of safe and effective vaccines to prevent it. Ninety-five percent of child pneumococcal deaths occur in the developing world, largely unreached by the existing vaccines as yet.

WHO recommends that all countries prioritize introduction of PCV, particularly those with high child mortality rates. In 2000, the United States became the first country to license a 7-valent pneumococcal vaccine (PCV-7), which has virtually eliminated severe pneumococcal disease caused by vaccine serotypes in the U.S. Since then, 37 countries have implemented universal or widespread use of PCV-7, nearly all of which are in the industrialized world. New financial mechanisms, including the GAVI Alliance's Advance Market Commitment, are now in place to help low-income countries prevent pneumococcal deaths in their own countries. Next generation PCVs are expected to shortly become available and will provide expanded serotype coverage of strains common in the developing world.

"While early detection and treatment can save lives, this review highlights the effectiveness of pneumococcal conjugate vaccines for preventing pneumococcal disease before it occurs," said Dr. Orin Levine, executive director of PneumoADIP at the Johns Hopkins Bloomberg School of Public Health. "Low-income countries can now have the opportunity to introduce pneumococcal vaccine on an unprecedented timetable and at prices their governments can afford. We recommend that all countries eligible for GAVI support apply now and take immediate steps to prioritize prevention."

More information: For more information on the study, please visit www.cochrane.org/reviews/en/ab004977.html

Source: Johns Hopkins University Bloomberg School of Public Health (news : web)

Explore further: High-dose flu vaccine appears better for frail older adults in long-term care

add to favorites email to friend print save as pdf

Related Stories

Pediatric vaccine effectively prevents pneumococcal meningitis

Jan 14, 2009

A standard pediatric vaccine used to prevent several common types of life-threatening infections also effectively reduced the rates of another disease, pneumococcal meningitis, in children and adults, according to a multi-center ...

Pneumococcal disease rates down significantly post-vaccine

Mar 18, 2008

Since the approval of a vaccine against pneumococcal bacteria for young children in 2000, rates of invasive pneumococcal disease (IPD) are down significantly in all age groups, while rates of IPD caused by non-vaccine strains ...

Recommended for you

Researchers ferret out a flu clue

3 hours ago

Research that provides a new understanding as to why ferrets are similar to humans is set to have major implications for the development of novel drugs and treatment strategies.

In the battle against Ebola, a double-layer solution

6 hours ago

When working with Ebola patients, protective gear works, but removing it can be harrowing. Seeking to protect health care workers from the precarious nature of taking off soiled gloves, Cornell students have ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.